SecBot SecBot
SECBOTREPLAY Home › Report › NKTX

NKTX · Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of…

Nkarta, Inc. · PRESS-RELEASE filed May 12, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed May 12, 2026 at 16:01 ET

Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FDA agreement for outpatient dosing and expansion into rheumatoid arthritis, with initial clinical data expected in 2026. Cash runway into 2029 provides stability, but the EPS miss and lack of near-term catalysts keep sentiment neutral.

  • Q1 2026 EPS: -$0.37 vs consensus -$0.36 (miss of 2.8%)
  • No revenue reported (pre-revenue biotech)
  • Cash balance: $266.7M as of March 31, 2026, expected to fund operations into 2029
  • Net loss: $27.8M for Q1 2026, improved from $32.0M in Q1 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access